Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Theraclone Sciences has reported that Zenyaku Kogyo has exercised its option for an exclusive license in the Japan territory to Theraclone’s influenza monoclonal antibody program.
Subscribe to our email newsletter
The collaboration utilises Theraclone’s I-Star technology to discover protective monoclonal antibodies for the treatment of pandemic influenza and severe seasonal influenza.
Sofar, Theraclone has received over $9m in fees, research milestone payments, and an equity investment from Zenyaku Kogyo for this program. Total potential funding for the program is $18m through Phase 1 clinical trials.
In addition, Theraclone is eligible to receive clinical milestone payments and royalties from potential future sales in the territory. Theraclone shall retain worldwide development and commercial rights outside of Japan.
Wherein, Zenyaku Kogyo shall be eligible to receive a share of proceeds from Theraclone’s licensing of rights in Asian countries outside of Japan.
David Fanning, president and CEO of Theraclone Sciences, said: “We have worked very closely and effectively with Zenyaku Kogyo over the past six months to reach key milestones in our influenza monoclonal antibody partnership. Both Theraclone and Zenyaku Kogyo are very encouraged by initial results and we look forward to our continued strong development relationship.”